Arissa Medical Progresses with Syntra Device in Cerebral Aneurysm Treatment Study

NEWARK, CA (July 2024) – Arissa Medical, Inc., a privately held medical device company based in Newark, has made strides in its Syntra study by enrolling its third group of patients. This pilot study is focused on evaluating the safety and effectiveness of their innovative intrasaccular scaffold device, designed to treat wide-neck intracranial aneurysms, including those that are irregular and located at bifurcations.

The latest procedures were successfully completed at the Instituto de Neurocirugía Dr. Alfonso Asenjo in Santiago, Chile, with interventional neuroradiologist Dr. Juan Gabriel Sordo leading the efforts as the principal investigator.

In a press release, Arissa Medical reported that both Gary Duckwiler from UCLA and Luis Augusto Lemme from Argentina—who were involved in early testing—highlighted the device’s smooth delivery and flexibility in treating difficult aneurysms. They noted that there have been no technical issues, and patients are recovering well.

The Syntra device introduces a unique intrasaccular framework that improves coverage of the aneurysm neck, reducing its diameter and supporting coiling procedures. A key advantage of this device is that it removes the need for dual antiplatelet medications due to its purely intrasaccular approach.

To learn more about this exciting development and what lies ahead for the study, click the button below for the full article.